<DOC>
	<DOCNO>NCT00727532</DOCNO>
	<brief_summary>RATIONALE : Sorafenib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Giving sorafenib surgery may make tumor small reduce amount normal tissue need remove . PURPOSE : This clinical trial study well sorafenib work treat patient locally advance metastatic kidney cancer .</brief_summary>
	<brief_title>Sorafenib Treating Patients With Locally Advanced Metastatic Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To demonstrate feasibility safety sorafenib tosylate give prior nephrectomy metastasectomy . - To evaluate ability diffusion-weighted magnetic resonance imaging ( DW-MRI ) detect early ongoing microstructural change primary metastatic renal cell carcinoma lesion neoadjuvant therapy sorafenib tosylate . - To correlate early ongoing microstructural change primary metastatic renal cell carcinoma lesion pathologic clinical finding time nephrectomy metastasectomy . - To evaluate ability change DW-MRI predict subsequent favorable response treatment ( complete partial response stable disease ) 4 week therapy . OUTLINE : Patients receive oral sorafenib tosylate twice daily day 1-28 . Patients undergo nephrectomy metastasectomy week 5 . Patients residual metastatic disease may continue sorafenib tosylate twice daily undergo diffusion-weighted MRI ( DW-MRI ) every 8 week absence disease progression unacceptable toxicity . Patients undergo DW-MRI abdomen pelvis baseline prior week 5 evaluate microstructure tumor change allow prediction sorafenib tosylate benefit . DW-MRI result correlate surgical pathologic finding obtain week 5 . Resected tumor tissue analyze vascular density distinguish apoptotic cell death necrotic cell death via immunohistochemistry measure apoptotic cell death via TUNEL assay . After completion study treatment , patient follow every 3 month 2 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm newly diagnose clear cell renal cell carcinoma , meet 1 follow criterion : Localized disease , evidence intact , bulky , primary renal lesion ( T1 &gt; 3 cm , T2 , T3 , T4 ) appropriate nephrectomy Limited metastatic disease , evidence renal primary ( T1 &gt; 3 cm , T2 , T3 , T4 ) appropriate cytoreductive nephrectomy Isolated abdominal/pelvic recurrence limit metastatic burden ( minimum size &gt; 2 cm ) appropriate metastasectomy No known brain metastasis Patients neurological symptom must undergo CT scan/MRI brain exclude brain metastasis PATIENT CHARACTERISTICS : ECOG performance status 01 Hemoglobin ≥ 9.0 g/dL ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) ALT AST ≤ 2.5 time ULN ( ≤ 5 time ULN liver involvement ) Creatinine ≤ 1.5 time ULN Estimated glomerular filtration rate &gt; 30 mL/min ( patient receive Gdenhanced MRI ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception prior , ( men woman ) , least 3 month ( men ) completion study therapy Adequate cardiac pulmonary status operative therapy No active clinically serious infection &gt; CTCAE grade 2 No know HIV , hepatitis B , hepatitis C infections No serious nonhealing wound , ulcer , bone fracture No significant traumatic injury withing past 4 week No pulmonary hemorrhage/bleeding event ≥ CTCAE grade 2 within past 4 week No hemorrhage/bleeding event ≥ CTCAE grade 3 within past 4 week No history uncontrolled bleed disorder include , limited , follow : Bleeding diathesis Coagulopathy No cardiac disease condition include , limited , follow : New York Heart Association class IIIV congestive heart failure Unstable angina ( anginal symptom rest ) New onset angina begin within last 3 month Myocardial infarction within past 6 month Cardiac ventricular arrhythmia require antiarrhythmic therapy No uncontrolled hypertension ( i.e. , systolic blood pressure [ BP ] &gt; 150 mm Hg diastolic BP &gt; 100 mm Hg ) despite optimal medical management No thrombolic embolic event within past 6 month ( e.g. , cerebrovascular accident include transient ischemic attack ) No condition impair ability swallow whole pill No malabsorption problem No contraindication MRI , include , limited , follow : Ferromagnetic implant Dental work Pacemakers Metallic implant Severe claustrophobia precludes close MRI test No known suspect allergy sorafenib tosylate No contraindication allergy gadolinium ( e.g. , end stage renal disease require hemodialysis ) No intercurrent illness situation , judgment investigator , would affect assessment clinical status study endpoint significantly PRIOR CONCURRENT THERAPY : See Disease Characteristics More 4 week since prior major surgery open biopsy No prior therapy tyrosine kinase VEGF inhibitor ( e.g. , sunitinib malate , sorafenib , bevacizumab ) No concurrent Hypericum perforatum ( St. John 's wort ) rifampin No concurrent use illicit drug substance may , opinion investigator , reasonable chance contribute toxicity interfere study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>clear cell renal cell carcinoma</keyword>
	<keyword>hereditary clear cell renal cell carcinoma</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>stage I renal cell cancer</keyword>
	<keyword>stage II renal cell cancer</keyword>
	<keyword>stage III renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
</DOC>